120 research outputs found
Recommended from our members
Editorial: Debates in Clinical Management in Pediatric Endocrinology.
Recommended from our members
Editorial: Debates in Clinical Management in Pediatric Endocrinology.
Recommended from our members
Editorial: Debates in Clinical Management in Pediatric Endocrinology
High Sclerostin and Dickkopf-1 (DKK-1) serum levels in children and adolescents with type 1 diabetes mellitus
CONTEXT:
Childhood type 1 diabetes (T1DM) is associated with decreased bone mass. Sclerostin and dickkopf-1 (DKK-1) are Wnt inhibitors which regulate bone formation.
OBJECTIVE:
To evaluate sclerostin and DKK-1 levels in TD1M children and to analyze the influence of the glycaemic control on bone health.
DESIGN AND SETTING:
Cross-sectional study conducted at a clinical research center. Partecipants: One hundred and six T1DM subjects (12.2 ± 4 years), 66 on multiple daily injections (MDI) and 40 on continuous subcutaneous infusion of insulin (CSII), and 80 controls.
RESULTS:
The average of bone transmission time (BTT) and amplitude-dependent speed of sound (Ad-Sos) Z-scores was lower in diabetics than controls. Significant increased DKK-1 (3593 ± 1172 vs 2652 ± 689 pg/ml, p<0.006) and sclerostin (29.45 ± 12.32 vs 22.53 ± 8.29, p<0.001) levels were found in diabetics respect to controls, particularly in patients on MDI than ones on CSII. Glycaemic control was improved in CSII patients compared to MDI ones (p<0.001) and was also associated to a significant higher BMI-SDS (p<0.002) and BTT-Z-score (p<0.02). With adjustment for age multiple linear regression analysis for DKK-1 and sclerostin as dependent variables showed that levels of HbA1c%, glucose, 25(OH)-Vitamin D, osteocalcin, PTH, years of diabetes, BMI-SDS and AD-SoS-Z-score are the most important predictors (p<0.0001).
CONCLUSIONS:
Our study highlighted: 1. the high serum levels of DKK-1 and sclerostin in T1DM children, and their relationship with the altered glycaemic control; 2. the effect of CSII on the improvement of glycaemic control and bone health in T1DM children
Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors
Vitamin D (25-OHD) has a role in bone health after treatment for cancer. 25-OHD deficiency has been associated with risk factors for cardiovascular disease, but no data focusing on this topic in childhood cancer survivors have been published. We investigated the 25-OHD status in children treated for acute lymphoblastic leukemia (ALL), and evaluated its influence on vascular function
Dietary cholesterol supplementation and inhibitory factor 1 serum levels in two dizygotic Smith-Lemli-Opitz syndrome twins: a case report
Smith-Lemli-Opitz syndrome (SLOS) is a rare genetic neurodevelopmental disorder caused by the defect in the 7-dehydrocholesterol reductase. This defect leads to the deficiency of cholesterol biosynthesis with accumulation of 7-dehydrocholesterol. Inhibitory factor 1 (IF1) is a well-known mitochondrial protein. Recently, it has been discovered in the human serum where it is reported to be involved in the HDL-cholesterol intake. Here we report the IF1 presence in the serum of two paediatric SLOS dizygotic twins treated with dietary cholesterol supplementation
Non-alcoholic fatty liver disease is associated with early left ventricular dysfunction in childhood acute lymphoblastic leukaemia survivors.
Background: Childhood acute lymphoblastic leukaemia (ALL) survivors have an increased risk of metabolic and
cardiovascular disease. We aimed to assess the presence of non-alcoholic fatty liver disease (NAFLD) in childhood ALL
and if it is associated with early cardiovascular dysfunction.
Methods: In total, 53 childhood ALL survivors and 34 controls underwent auxological evaluation, biochemical assay,
liver, heart and vascular ultrasound study.
Results: NAFLD was more frequent in ALL patients than in controls (39.6% vs 11.7%, P < 0.01). Patients with NAFLD
were more obese and insulin resistant than patients without NAFLD. Flow-mediated dilatation and interventricular
septum were lower in the ALL group than those in the control group (P < 0.001 for both). The patients with NAFLD
showed lower left ventricular ejection fraction than those without NAFLD (P = 0.011). In ALL survivors, BMI-SDS and
subcutaneous fat were the strongest predictors of NAFLD, whereas preperitoneal adipose tissue and C-reactive protein
were the strongest predictors of left ventricular ejection fraction.
Conclusions: Childhood ALL survivors had higher prevalence of NAFLD than healthy controls, which is associated
with early left ventricular impairment. In the case of fatty liver, a comprehensive heart evaluation is mandatory. We
strongly recommend to prevent visceral adiposity in ALL survivors, to search for metabolic
syndrome or its components and to reinforce the need of intervention on diet and lifestyle
during the follow-up of these patients
- …